Paper978134
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG and 2 others. J Exp Med, 1976. Cited by 193 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. Papers, record 978134. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/978134
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Complement C3 | Major topic |
| Complement C5 | Major topic |
| Complement System Proteins | Major topic |
| Esterases | Major topic |
| Properdin | Major topic |
| Protein Precursors | Major topic |
| Animals | |
| Cell Membrane | |
| Erythrocytes | |
| Humans | |
| In Vitro Techniques | |
| Sheep |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14,316,946 | ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. | J Exp Med | 1965 | https://conductscience.org/library/papers/14316946 | PubMed |
| 2 | 6,019,133 | Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. | J Exp Med | 1967 | https://conductscience.org/library/papers/6019133 | PubMed |
| 3 | 62,010 | Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. | J Exp Med | 1976 | https://conductscience.org/library/papers/62010 | PubMed |
| 4 | 1,185,108 | Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. | J Exp Med | 1975 | https://conductscience.org/library/papers/1185108 | PubMed |
| 5 | 4,130,153 | The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase. | J Immunol | 1974 | https://conductscience.org/library/papers/4130153 | PubMed |
| 6 | 4,111,773 | C3 proactivator convertase and its mode of action. | J Exp Med | 1972 | https://conductscience.org/library/papers/4111773 | PubMed |
| 7 | 4,160,044 | A method of trace iodination of proteins for immunologic studies. | Int Arch Allergy Appl Immunol | 1966 | https://conductscience.org/library/papers/4160044 | PubMed |
| 8 | 4,202,731 | Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. | J Exp Med | 1973 | https://conductscience.org/library/papers/4202731 | PubMed |
| 9 | 4,207,623 | A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. | J Exp Med | 1974 | https://conductscience.org/library/papers/4207623 | PubMed |
| 10 | 2,647 | Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement. | J Exp Med | 1976 | https://conductscience.org/library/papers/2647 | PubMed |
| 11 | 4,477,550 | Studies on the sub-unit structure of human properdin. | Immunochemistry | 1974 | https://conductscience.org/library/papers/4477550 | PubMed |
| 12 | 4,808,709 | The role of properdin in the alternate pathway of complement activation. | J Exp Med | 1974 | https://conductscience.org/library/papers/4808709 | PubMed |
| 13 | 4,795,621 | The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway. | J Immunol | 1973 | https://conductscience.org/library/papers/4795621 | PubMed |
| 14 | 4,818,459 | Isolation and characterization of the proenzyme form of the C1r subunit of the first complement component. | J Immunol | 1974 | https://conductscience.org/library/papers/4818459 | PubMed |
| 15 | 5,058,233 | Molecular analysis of the membrane attack mechanism of complement. | J Exp Med | 1972 | https://conductscience.org/library/papers/5058233 | PubMed |
| 16 | 5,329,367 | A molecular concept of immune cytolysis. | Arch Pathol | 1966 | https://conductscience.org/library/papers/5329367 | PubMed |
| 17 | 808,993 | Inhibition of complement-derived enzymes. | Ann N Y Acad Sci | 1975 | https://conductscience.org/library/papers/808993 | PubMed |
| 18 | 1,059,108 | Properdin: initiation of alternative complement pathway. | Proc Natl Acad Sci U S A | 1975 | https://conductscience.org/library/papers/1059108 | PubMed |
| 19 | 1,249,415 | Purification of the sixth and seventh component of human complement without loss of hemolytic activity. | J Immunol | 1976 | https://conductscience.org/library/papers/1249415 | PubMed |
| 20 | 1,165,475 | Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. | J Exp Med | 1975 | https://conductscience.org/library/papers/1165475 | PubMed |
Cited by74
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 193 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,131,334 | Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome. | Front Immunol | 2026 | https://conductscience.org/library/papers/42131334 | PubMed |
| 41,159,389 | Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/41159389 | PubMed |
| 40,904,461 | The complement system in human pregnancy and preeclampsia. | Front Immunol | 2025 | https://conductscience.org/library/papers/40904461 | PubMed |
| 36,853,837 | A Monoclonal Antibody That Provides a Model for C3 Nephritic Factors. | Monoclon Antib Immunodiagn Immunother | 2023 | https://conductscience.org/library/papers/36853837 | PubMed |
| 36,713,423 | A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution. | Front Immunol | 2022 | https://conductscience.org/library/papers/36713423 | PubMed |
| 35,517,827 | Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35517827 | PubMed |
| 34,671,342 | Modulation of the Complement System by Neoplastic Disease of the Central Nervous System. | Front Immunol | 2021 | https://conductscience.org/library/papers/34671342 | PubMed |
| 33,801,255 | The Brilliance of Borrelia: Mechanisms of Host Immune Evasion by Lyme Disease-Causing Spirochetes. | Pathogens | 2021 | https://conductscience.org/library/papers/33801255 | PubMed |
| 33,542,722 | Prognostic Value of Complement Properdin in Cancer. | Front Immunol | 2020 | https://conductscience.org/library/papers/33542722 | PubMed |
| 33,329,546 | Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life. | Front Immunol | 2020 | https://conductscience.org/library/papers/33329546 | PubMed |
| 32,909,942 | Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement. | Elife | 2020 | https://conductscience.org/library/papers/32909942 | PubMed |
| 32,274,388 | Regulation of anti-microbial autophagy by factors of the complement system. | Microb Cell | 2020 | https://conductscience.org/library/papers/32274388 | PubMed |
| 31,736,953 | Urinary Properdin and sC5b-9 Are Independently Associated With Increased Risk for Graft Failure in Renal Transplant Recipients. | Front Immunol | 2019 | https://conductscience.org/library/papers/31736953 | PubMed |
| 31,552,043 | Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b. | Front Immunol | 2019 | https://conductscience.org/library/papers/31552043 | PubMed |
| 31,214,159 | C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31214159 | PubMed |
| 30,487,789 | Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. | Front Immunol | 2018 | https://conductscience.org/library/papers/30487789 | PubMed |
| 30,141,176 | The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy? | Pediatr Nephrol | 2019 | https://conductscience.org/library/papers/30141176 | PubMed |
| 30,135,690 | Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases. | Front Immunol | 2018 | https://conductscience.org/library/papers/30135690 | PubMed |
| 29,954,621 | Properdin: A multifaceted molecule involved in inflammation and diseases. | Mol Immunol | 2018 | https://conductscience.org/library/papers/29954621 | PubMed |
| 29,167,939 | The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation? | Semin Immunopathol | 2018 | https://conductscience.org/library/papers/29167939 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| C5 | 727 | PubTator's text mining | https://conductscience.org/library/genes/727 | NCBI Gene |
| CFB | 629 | PubTator's text mining | https://conductscience.org/library/genes/629 | NCBI Gene |
| CFH | 3,075 | PubTator's text mining | https://conductscience.org/library/genes/3075 | NCBI Gene |
| CFI | 3,426 | PubTator's text mining | https://conductscience.org/library/genes/3426 | NCBI Gene |
| CFP | 5,199 | PubTator's text mining | https://conductscience.org/library/genes/5199 | NCBI Gene |
| ERVK-3 | 100,862,689 | PubTator's text mining | https://conductscience.org/library/genes/100862689 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/978134
GET https://conductscience.org/api/papers/v1/978134/references?page=2